Terms: = Liver cancer AND CHEK2, bA444G7, 11200, ENSG00000183765, O96017, RAD53, RP11-436C9_1, PP1425, LFS2, CHK2, HuCds1 AND Prognosis
10409 results:
1. Epstein
Peng L; Peng X; Duan S; Zhang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):319-330. PubMed ID: 38755729
[TBL] [Abstract] [Full Text] [Related]
2. Patterns of distant metastasis and survival outcomes in
Liu K; Huang AL; Chen XQ; Wu SG
Front Endocrinol (Lausanne); 2024; 15():1385756. PubMed ID: 38752173
[TBL] [Abstract] [Full Text] [Related]
3. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
4. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
Wang Y; Lu BH; Gao Y; Liu YX; Hu MM; Che NY; Lin HF; Li HX; Zhang HM; Zhang TM
Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):419-427. PubMed ID: 38742355
[No Abstract] [Full Text] [Related]
5. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study.
Guo DZ; Huang A; Wang YC; Zhou S; Wang H; Xing XL; Zhang SY; Cheng JW; Xie KH; Yang QC; Ma CC; Li Q; Chen Y; Su ZX; Fan J; Liu R; Liu XL; Zhou J; Yang XR
Clin Transl Med; 2024 May; 14(5):e1652. PubMed ID: 38741204
[TBL] [Abstract] [Full Text] [Related]
6. Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma.
Dong B; Zhang H; Duan Y; Yao S; Chen Y; Zhang C
J Transl Med; 2024 May; 22(1):455. PubMed ID: 38741163
[TBL] [Abstract] [Full Text] [Related]
7. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
Zhao J; Liu Z; Yang K; Shen S; Peng J
Front Immunol; 2024; 15():1333923. PubMed ID: 38736884
[TBL] [Abstract] [Full Text] [Related]
8. Transcript and protein signatures derived from shared molecular interactions across cancers are associated with mortality.
Zhao Y; Li X; Loscalzo J; Smelik M; Sysoev O; Wang Y; Mahmud AKMF; Mansour Aly D; Benson M
J Transl Med; 2024 May; 22(1):444. PubMed ID: 38734658
[TBL] [Abstract] [Full Text] [Related]
9. DGPRI, a new liver fibrosis assessment index, predicts recurrence of AFP-negative hepatocellular carcinoma after hepatic resection: a single-center retrospective study.
Zhang B; Xue J; Xu B; Chang J; Li X; Huang Z; Zhao H; Cai J
Sci Rep; 2024 May; 14(1):10726. PubMed ID: 38730095
[TBL] [Abstract] [Full Text] [Related]
10. Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma.
Wang T; Han L; Xu J; Guo B
Medicine (Baltimore); 2024 May; 103(19):e37998. PubMed ID: 38728505
[TBL] [Abstract] [Full Text] [Related]
11. SOAT1 regulates cholesterol metabolism to induce EMT in hepatocellular carcinoma.
Fu R; Xue W; Liang J; Li X; Zheng J; Wang L; Zhang M; Meng J
Cell Death Dis; 2024 May; 15(5):325. PubMed ID: 38724499
[TBL] [Abstract] [Full Text] [Related]
12. IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p.
Gharib E; Rejali L; Piroozkhah M; Zonoobi E; Nasrabadi PN; Arabsorkhi Z; Baghdar K; Shams E; Sadeghi A; Kuppen PJK; Salehi Z; Nazemalhosseini-Mojarad E
J Transl Med; 2024 May; 22(1):439. PubMed ID: 38720389
[TBL] [Abstract] [Full Text] [Related]
13. Diacylglycerol kinase alpha is a proliferation marker of intrahepatic cholangiocarcinoma associated with the prognosis.
Shichi S; Sugiyama K; Asahi Y; Shirakawa C; Nakamoto H; Kimura S; Wakizaka K; Aiyama T; Nagatsu A; Orimo T; Kakisaka T; Taketomi A
Cancer Med; 2024 May; 13(9):e7238. PubMed ID: 38716625
[TBL] [Abstract] [Full Text] [Related]
14. [Analysis of factors affecting the prognosis of patients with pancreatic cancer patients with obstructive jaundice].
Zhang L; Li M; Sun QF; Yu HP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):474-479. PubMed ID: 38715484
[No Abstract] [Full Text] [Related]
15. GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
Qiao W; Li J; Xiong Y; Zheng J; Jin R; Hu C
J Cancer Res Clin Oncol; 2024 May; 150(5):241. PubMed ID: 38713414
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive Analysis of the Immunosuppressive Function of Regulatory T Cells in Human Hepatocellular Carcinoma Tissues.
Ge J; Chen J; Shen Q; Zheng X; Chen X; Shi L; Chen L; Xu B
Cancer Control; 2024; 31():10732748241251580. PubMed ID: 38712609
[TBL] [Abstract] [Full Text] [Related]
17. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract] [Full Text] [Related]
18. Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract] [Full Text] [Related]
20. Predicting effect of anti-PD-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract] [Full Text] [Related]
[Next]
